GHRS
Price
$19.25Alerts
Change
-$0.31 (-1.58%)
Updated
Nov 11 closing price
Capitalization
1.28B
One day until earnings call
Intraday BUY SELL Signals
IMRX
Price
$3.79Alerts
Change
-$0.06 (-1.56%)
Updated
Nov 11 closing price
Capitalization
238.09M
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GHRS vs IMRX

GHRS vs IMRX Comparison Chart in %
View a ticker or compare two or three
VS
GHRS vs. IMRX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GHRS is a Hold and IMRX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GHRS with price predictions
Nov 10, 2026

GHRS in +5.10% Uptrend, advancing for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GHRS advanced for three days, in 249 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GHRS's RSI Oscillator exited the oversold zone, 16 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for GHRS just turned positive on October 23, 2026. Looking at past instances where GHRS's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GHRS as a result. In 88 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

GHRS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GHRS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.553) is normal, around the industry mean (3.498). P/E Ratio (-18.798) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. GHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for IMRX with price predictions
Nov 10, 2026

IMRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026

IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 37 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on IMRX as a result. In 80 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.

Following a +7.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 220 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for IMRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (3.498). P/E Ratio (-3.957) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
GHRSIMRX
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 8 days ago
88%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (GHRS: $19.56 vs. IMRX: $3.85)
Brand notoriety: GHRS and IMRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GHRS: 26% vs. IMRX: 86%
Market capitalization -- GHRS: $1.28B vs. IMRX: $238.09M
GHRS [@Biotechnology] is valued at $1.28B. IMRX’s [@Biotechnology] market capitalization is $238.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GHRS’s FA Score shows that 2 FA rating(s) are green while IMRX’s FA Score has 1 green FA rating(s).

  • GHRS’s FA Score: 2 green, 3 red.
  • IMRX’s FA Score: 1 green, 4 red.
According to our system of comparison, GHRS is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GHRS’s TA Score shows that 4 TA indicator(s) are bullish while IMRX’s TA Score has 6 bullish TA indicator(s).

  • GHRS’s TA Score: 4 bullish, 4 bearish.
  • IMRX’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, IMRX is a better buy in the short-term than GHRS.

Price Growth

GHRS (@Biotechnology) experienced а -3.55% price change this week, while IMRX (@Biotechnology) price change was +4.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

GHRS is expected to report earnings on Nov 12, 2026.

IMRX is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

GHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with STTK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GHRS
1D Price
Change %
GHRS100%
+1.56%
STTK - GHRS
44%
Loosely correlated
-2.81%
FDMT - GHRS
40%
Loosely correlated
-0.16%
IMRX - GHRS
39%
Loosely correlated
+5.48%
VIR - GHRS
38%
Loosely correlated
-3.63%
SANA - GHRS
37%
Loosely correlated
-1.42%
More

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with ACRV. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then ACRV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
+5.48%
ACRV - IMRX
52%
Loosely correlated
-0.63%
CRMD - IMRX
50%
Loosely correlated
-1.83%
JSPR - IMRX
40%
Loosely correlated
-9.90%
LXEO - IMRX
40%
Loosely correlated
-2.55%
GHRS - IMRX
39%
Loosely correlated
+1.56%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PCAR105.570.19
+0.18%
PACCAR
CBLL27.48-0.12
-0.43%
CERIBELL INC
CMND5.39-0.06
-1.10%
Clearmind Medicine Inc.
DNTH88.81-1.19
-1.32%
Dianthus Therapeutics
FATE1.77-0.17
-8.76%
Fate Therapeutics